Interim Effectiveness Estimates of 2023 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalizations — REVELAC–i Network, March–July 2023

Evaluations of vaccine effectiveness during the March– September Southern Hemisphere influenza season can provide valuable information for countries currently experiencing the influenza season and preceding the October–May Northern Hemisphere influenza season. Since 2013, multiple countries have participated in the Network for the Evaluation of Vaccine Effectiveness in Latin America and the Caribbean–influenza (la Red para la Evaluación de Vacunas en Latino América y el Caribe—influenza [REVELAC–i]) to estimate and monitor vaccine effectiveness (VE) in preventing severe acute respiratory infection (SARI)–associated hospitalization. Based on data contributed by Argentina, Brazil, Chile, Paraguay, and Uruguay on 2,780 SARI patients hospitalized during March 27–July 9, 2023, the adjusted VE against SARI hospitalization associated with any influenza virus during the 2023 Southern Hemisphere season was 51.9% (95% Confidence Interval [CI] 39.2%– 62.0%), including 55.2% (95% CI: 41.8%–65.5%) against the predominating A(H1N1)pdm09. These early, interim estimates, provided before the expected end of seasonal influenza virus circulation, suggest that vaccination substantially reduced the risk for severe influenza illnesses, underscoring


Introduction
In Latin American and Caribbean countries, influenza viruses have been associated with 716,000-829,000 respiratory hospitalizations and 41,007-71,710 deaths each year (1).Despite a history of high influenza vaccination coverage in the * These authors contributed equally to this report.region, declines in coverage since 2019 have been observed.Systematic monitoring of influenza and COVID-19 vaccine effectiveness (VE), as is conducted through the Pan American Health Organization's Network for the Evaluation of Vaccine Effectiveness in Latin America and the Caribbean-influenza (la Red para la Evaluación de Vacunas en Latino América y el Caribe-influenza [REVELAC-i]) † can be helpful in supporting public messaging to improve vaccination coverage (2).In addition, VE estimates from countries in the Southern Hemisphere during the March-September influenza season can provide insight into the effectiveness of vaccines for use during the subsequent October-May Northern Hemisphere influenza season (3).

Methods
VE against influenza-associated hospitalization was estimated using a test-negative case-control study design to compare the odds of vaccination between hospitalized patients with a positive influenza test result (test-positive patients [case-patients]) and influenza test-negative hospitalized control patients.Patients meeting criteria for severe acute respiratory infection (SARI), defined as acute respiratory infection with a history of fever or documented temperature of ≥100.4°F[≥38°C] and cough, with onset during the preceding 10 days resulting in hospitalization, were identified through sentinel SARI surveillance using a standardized protocol (4).Respiratory specimens were collected and tested for influenza virus type and subtype by reverse transcription-polymerase chain reaction (RT-PCR) in national reference laboratories.
During March 27-July 9, 2023, midseason data were available and were pooled from 486 sentinel hospitals, including 11 in Argentina, 455 in Brazil, eight in Chile, two in Paraguay, and 10 in Uruguay.Because influenza was circulating in the Southern Hemisphere earlier than usual and before the start of influenza vaccination campaigns, the VE evaluation began 2 weeks after each country's annual national influenza vaccination campaign.§ Participating countries used a Southern Hemisphere formulation of † https://www.paho.org/en/network-evaluation-vaccine-effectiveness-latinamerica-and-caribbean-influenza-revelac-i(5).
The evaluation population was restricted to SARI patients in three mutually exclusive target groups for vaccination based on national immunization policies.The criteria for each group varied slightly by country, but included 1) young children, 2) persons with preexisting conditions, and 3) older adults.¶ Case-patients were defined as SARI patients with a positive RT-PCR influenza test result.Control patients were defined as SARI patients with negative RT-PCR test results for both influenza and SARS-CoV-2.Patient vaccination status was ascertained via linkage to national electronic immunization records using unique patient identifiers.
Patients who received ≥1 dose of the 2023 season influenza vaccine ≥14 days before symptom onset were considered vaccinated; those who did not receive any influenza vaccine during the 2023 season before symptom onset were considered unvaccinated.Patients vaccinated <14 days before symptom onset or who had positive SARS-CoV-2 RT-PCR test results were excluded from the evaluation to avoid the risk for confounding (6).
VE was estimated using mixed effects logistic models adjusting for age in years (fit as cubic spline), week of symptom onset (fit as cubic spline), and presence of at least one preexisting condition, and accounting for country as a random effect.Analyses were stratified by influenza type and subtype (when available) and presented when data were sufficient (at least five patients contributing to all strata) or when the 95% CI of the VE estimate was <140%.P-values <0.05 and 95% CIs that did not include zero were considered statistically significant.This activity was reviewed by CDC and conducted consistent with applicable federal law and CDC policy.**

Results
During March 27-July 9, 2023, a total of 3,974 SARI hospitalizations among persons prioritized to receive influenza vaccination in Argentina, Brazil, Chile, Paraguay, and Uruguay were identified.Among these, 1,194  Among SARI patients, 15.3% of case-patients had received a 2023 seasonal influenza vaccine, compared with 28.0% of control patients (Table 2).Overall adjusted VE against influenza-associated SARI hospitalization was 51.9%.VE among young children was 70.2%, and among older adults was 37.6% When limited to influenza A(H1N1)pdm09, which predominated during the 2023 Southern Hemisphere season, VE against SARI hospitalization was 55.2%, similar to overall estimates and consistent among target populations.Estimated VE for influenza B (Victoria) was not statistically significant (95% CI included zero) (Table 2), and insufficient numbers of vaccinated case-patients with influenza A(H3N2) precluded estimation of virus-specific VE.
As of August 15, 2023, a total of 1,031 influenza viruses had been genetically characterized by CDC, and the five countries' laboratories reported the isolates to the Global Initiative on Sharing All Influenza Data.† † The majority of viruses were characterized as belonging to the same genetic clades as the 2023 Southern Hemisphere vaccine components: among Abbreviations: RT-PCR = reverse transcription-polymerase chain reaction; SARI = severe acute respiratory infection.* Patients who received ≥1 dose of the 2023 season influenza vaccine ≥14 days before symptom onset were considered vaccinated; patients who did not receive any influenza vaccine during the 2023 season by the time of symptom onset were considered unvaccinated.Patients vaccinated 0-14 days before symptom onset or with positive SARS-CoV-2 RT-PCR test results were excluded from the evaluation to avoid the risk of confounding.† A Pearson's chi-square test was used to ascertain whether there were differences in the numbers of persons who were vaccinated and unvaccinated or who received positive and negative influenza test results.§ Target groups are presented as mutually exclusive groups of persons considered at high risk for severe outcomes associated with influenza infection.Within countries, young children were defined as the following age groups: Argentina = 6 months-2 years; Paraguay = 6 months-3 years; Chile and Uruguay = 6 months-5 years; and Brazil = 6 months-6 years.Older adults were defined as aged ≥60 years (Brazil and Paraguay) and aged ≥65 years (Argentina, Chile, and Uruguay).The preexisting conditions tracked by REVELAC-i are asthma, cancer, hypertension, diabetes, cardiovascular disease, respiratory disease (excluding asthma), obesity, and immunocompromise.¶ Number of all SARI patients with preexisting conditions, including young children and older adults.570 A(H1N1)pdm09 viruses, 309 (54.2%) belonged to subclade 5a.2a.1, 259 (45.4%) to subclade 5a.2a, and two (0.4%) to subclade 5a.1.Among six A(H3N2) viruses, three belonged to clade 3C.2a1b.2a.2 subclade 2a.1b and three to subclade 2b.All B/Victoria viruses belonged to subclade V1A.3a.2.

Discussion
This interim evaluation of the 2023 Southern Hemisphere influenza vaccine formulation was conducted using data from five Southern Hemisphere countries and suggests that the current season's trivalent and quadrivalent inactivated influenza vaccines are effective in reducing influenza-associated hospitalization.In particular, interim VE estimates indicate a significant reduction in hospitalization associated with the predominant influenza A(H1N1)pdm09 virus among young children and older adults.Vaccination is one of the most effective ways to prevent influenza and severe associated outcomes.
Health authorities worldwide should encourage influenza vaccination for persons at increased risk for severe disease, including young children, persons with preexisting health conditions, and older adults, as well as those at increased risk for exposure to or transmission of influenza virus, such as health care personnel (3,7).
Despite the encouraging influenza VE, fewer than 30% of persons identified through REVELAC-i were vaccinated against influenza before their illness onset.The current findings were consistent with an interim report from Peru, where unadjusted VE against RT-PCR-confirmed influenza illness was 62%, but only one in five persons with medically attended respiratory illness had sought vaccination during 2023 (8), which is lower than the historical norm (2).Evaluations of influenza illness and vaccine knowledge, attitudes, and practices and deployment of World Health Organization (WHO) influenza post-introduction evaluations might help health  * Reverse transcription polymerase-chain reaction testing for influenza was conducted at national reference laboratories.† Vaccine effectiveness was estimated using mixed effects logistic models adjusting for age in years (fit as cubic spline), week of onset of symptoms (fit as cubic spline), and presence of at least one preexisting condition and accounting for country as a random effect.§ Within counties, young children were defined as the following age groups: Argentina = 6 months-2 years; Paraguay = 6 months-3 years; Chile and Uruguay = 6 months-5 years; and Brazil = 6 months-6 years.Older adults were defined as aged ≥60 years (Brazil and Paraguay) and aged ≥65 years (Argentina, Chile, and Uruguay).
authorities understand the reasons for reduced vaccination coverage since the COVID-19 pandemic and optimize influenza vaccination coverage in the future.§ § Although the timing and intensity of influenza epidemics in one hemisphere are not necessarily predictive of subsequent § § https://apps.who.int/iris/handle/10665/70436epidemics in the opposite hemisphere, this report might help health officials in Northern Hemisphere jurisdictions prepare for a potentially early influenza season and highlight the benefits of vaccination.In recent weeks, most influenza detections in the United States have identified A(H1N1) pdm09 and B/Victoria viruses (9).This is a similar pattern to that identified among the evaluated Southern Hemisphere countries, providing an encouraging outlook for vaccine protection from current influenza A(H1N1)pdm09 and influenza B/Victoria, because the Northern Hemisphere vaccine formulation contains antigenically similar A/Victoria/4897/2022 (H1N1)pdm09-like virus for egg-based vaccines and A/Wisconsin/67/2022 (H1N1)pdm09-like virus for cell-based vaccines.Nevertheless, whether influenza A(H1N1)pdm09 will remain the predominant virus in the United States during the October 2023-May 2024 Northern Hemisphere influenza season is unclear.
In advance of the WHO Vaccine Composition Meeting in September 2023, these data suggest that the influenza A/Sydney/5/2021 (H1N1)pdm09-like and B/Austria/1359417/2021 (B/Victoria lineage) viruses in the Southern Hemisphere vaccine formulation confer protection against influenza hospitalization; however, for the A/Darwin/9/2021 (H3N2)-like virus, VE estimates from other countries in the Southern Hemisphere, such as South Africa, which has a more substantial influenza A(H3N2) cocirculation, will be needed (10).Influenza B/Yamagata lineage has not circulated globally since 2020, and ongoing monitoring will be needed to determine if B/Yamagata antigens should remain in future influenza vaccine formulations.

Limitations
The findings in this report are subject to at least five limitations.First, the VE estimates are preliminary and represent only a 3-month period with a smaller analytic sample, resulting in some VE estimates with wide CIs.Second, nearly 25% of the 1,194 otherwise eligible patients were missing RT-PCR results for influenza and were excluded from analysis.Although the REVELAC-i protocol indicates RT-PCR testing for all patients meeting SARI criteria, limited hospital resources for surveillance specimen collection during high-incidence periods might result in incomplete testing.Third, although statistical models accounted for important sources of confounding, the potential for unmeasured confounding associated with the likelihood of hospitalization or propensity for vaccination remains.Fourth, VE estimates from the Southern Hemisphere are important for supporting routine influenza vaccination programs, but these results might not be generalizable to other countries in the region with different vaccine target groups, timing of vaccination campaigns, or viral clade circulation.Finally, this analysis was unable to disaggregate previously unvaccinated children aged 6 months-9 years who received 2 doses of influenza vaccine from those receiving only 1 dose; thus, it is possible that influenza VE among young children restricted to those who received 2 doses of influenza vaccines would have been higher than VE among those with only a first, priming dose (3).

Implications for Public Health Practice
Preliminary REVELAC-i data from five Southern Hemisphere countries suggest that influenza vaccines were effective in preventing more than one half of influenzaassociated hospitalizations among young children, persons with preexisting conditions, and older adults.The 2023-24 Northern Hemisphere influenza vaccine formulation contains antigenically similar A/Victoria/4897/2022 (H1N1)pdm09like virus (egg-based vaccines) and A/Wisconsin/67/2022 (H1N1)pdm09-like virus (cell-based vaccines) and might offer similar protection against influenza A(H1N1)pdm09 if these viruses predominate during the 2023-24 Northern Hemisphere influenza season.Evaluating influenza VE through integrated regional networks such as REVELAC-i provides valuable information that can guide public health practice.CDC and WHO recommend that health officials should encourage all eligible persons aged ≥6 months to seek influenza vaccination in accordance with national recommendations and to take other measures, including avoiding close contact with persons who are ill, to protect against influenza and potentially severe associated outcomes (3,7).Persons in the Northern Hemisphere who are at increased risk for influenza-associated complications, including children aged <2 years; persons with asthma; obesity; neurologic or neurodevelopmental conditions; blood disorders; chronic lung conditions; or endocrine, kidney, liver, metabolic, or heart diseases; who have had a stroke; or have a weakened immune system are especially encouraged to receive an influenza vaccination by September or October (7).

FIGURE.
FIGURE.Percentage of patients hospitalized with severe acute respiratory infection with positive influenza virus test results,* by epidemiologic week, among 2011-2019 sentinel surveillance reports and hospitalized patients (N = 2,780) -REVELAC-i Network, Argentina, Brazil, Chile, Paraguay, and Uruguay, March-July 2023